Part 1: M8891
Metastatic Renal Cell Carcinoma
EMD Serono Research & Development Institute, Inc.Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
298 Active assets in the Metastatic Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 4 | BBB |
gw786034 Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 4 | BBB |
Belzutifan Vall d'Hebron Institute of Oncology | Phase 3 | BBB |
Alpha-Interferon National Cancer Institute (NCI) | Phase 3 | BBB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Part 1: M8891 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →